Takeda Pharmaceutical Company Limited
Stock Price Chart
2026/03/02 UpdatedPrice Trend
2026/03/02 UpdatedPrice & Trading Details
2026/03/02 UpdatedPRICE
TRADING
Analyst Recommendations 15 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Top Mutual Funds / ETFs
Updated 2026/03/01Major Holders
Updated 2026/03/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
22.9M | +1.10% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
14.6M | +3.85% | |
|
CAPITAL WORLD GROWTH & INCOME FUND
|
12.9M | 0.00% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
10.7M | -0.77% | |
|
Goldman Sachs TRT II-Goldman Sachs GQG Part. Intl Opportunities Fd.
|
10.0M | +1.24% | |
|
Capital Income Builder
|
8.0M | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
1.9M | +1.33% | |
|
Paradigm Asset Management Company, LLC
|
1.6K | -96.96% |
Dividend History 3Years Growth
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥198 | +3.1% |
| 2024 | ¥192 | +4.3% |
| 2023 | ¥184 | +2.2% |
| 2022 | ¥180 | 0.0% |
| 2021 | ¥180 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥3,569,006M | ¥4,027,478M | ¥4,263,762M | ¥4,581,551M |
| Gross Profit | ¥2,462,160M | ¥2,783,406M | ¥2,837,084M | ¥3,001,334M |
| Operating Income | ¥546,043M | ¥587,812M | ¥366,165M | ¥486,061M |
| Pretax Income | ¥425,003M | ¥492,063M | ¥172,326M | ¥312,395M |
| Net Income | ¥230,059M | ¥317,017M | ¥144,067M | ¥107,928M |
| EPS | ¥145.87 | ¥201.94 | ¥91.16 | ¥67.23 |
| Operating Margin | 15.30% | 14.60% | 8.59% | 10.61% |
| Balance Sheet | ||||
| Total Assets | ¥13,178,018M | ¥13,957,750M | ¥15,108,792M | ¥14,248,344M |
| Total Equity | ¥5,683,019M | ¥6,354,122M | ¥7,273,264M | ¥6,935,084M |
| Total Liabilities | ¥7,494,999M | ¥7,603,628M | ¥7,835,528M | ¥7,313,260M |
| Cash | ¥849,695M | ¥533,530M | ¥457,800M | ¥385,113M |
| Interest-bearing Debt | ¥4,345,411M | ¥4,382,341M | ¥4,843,752M | ¥4,515,265M |
| Equity Ratio | 43.12% | 45.52% | 48.14% | 48.67% |
| D/E Ratio | 0.76 | 0.69 | 0.67 | 0.65 |
| Cash Flow | ||||
| Operating CF | ¥1,123,105M | ¥977,156M | ¥716,344M | ¥1,057,182M |
| Investing CF | -¥198,125M | -¥607,102M | -¥463,862M | -¥367,060M |
| Financing CF | -¥1,070,265M | -¥709,148M | -¥354,416M | -¥751,425M |
| Free CF | ¥937,068M | ¥343,467M | ¥235,614M | ¥677,557M |
| Efficiency | ||||
| ROE | 4.05% | 4.99% | 1.98% | 1.56% |
| ROA | 1.75% | 2.27% | 0.95% | 0.76% |
Latest IR Information
-
Acceptance of New Drug Application by the U.S. Food and Drug Administration for rusfertide, a Potential First-in-Class Treatment for Polycythemia Vera, in Collaboration with Protagonist Therapeutics, and Its Designation for Priority Review
Takeda Pharmaceutical announces that the U.S. FDA has accepted the new drug application for rusfertide, co-developed with Protagonist Therapeutics, and granted it priority review designation. The target date for review completion is Q3 2026.
Read more -
Acceptance of New Drug Application for Oveporexton (TAK-861), a Potential First-in-Class Treatment for Narcolepsy Type 1, by the U.S. Food and Drug Administration and Designation for Priority Review
Takeda Pharmaceutical has announced that the FDA has accepted the new drug application for oveporexton, a treatment for narcolepsy type 1, and designated it for priority review. The target date for review completion is Q3 2026.
Read more -
Takeda Pharmaceutical Company Limited (4502) Q3 Financial Summary for Fiscal Year Ending March 2026
For Q3 of fiscal year ending March 2026, consolidated revenue was 3,411.2 billion yen (3.3% YoY decrease), operating income was 422.4 billion yen (1.2% YoY increase), and quarterly profit was 216.3 billion yen (2.4% YoY increase), leading to an upward...
Read more -
(Correction) Partial correction regarding "Zasositinib for Plaque Psoriasis, Oral Once Daily Administration Shows Improvement in Skin Lesions and Possibility to Open a New Era of Treatment: Breakthrough Phase 3 Clinical Trial Data"
In the Phase 3 clinical trial of Zasositinib, the primary endpoints were achieved at week 16, with more than half of patients reaching PASI 90 and approximately 30% achieving PASI 100 indicating complete clearance of skin lesions. Safety profile was...
Read more -
Innovative Phase 3 Clinical Trial Data Demonstrates Zasositinib, Administered Once Daily Orally for Plaque Psoriasis, Improves Skin Lesions and Opens a New Era in Treatment
Zasositinib (TAK-279) achieved primary endpoints in a Phase 3 clinical trial targeting patients with moderate to severe plaque psoriasis, with over half achieving PASI90 and approximately 30% achieving PASI100 at week 16.
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥5,537
Rating Score: 2.13 (Based on 15 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.
